Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial

INTRODUCTION: Effective treatments are urgently needed to tackle the novel coronavirus disease 2019 (COVID-19). This trial aims to evaluate sofosbuvir and daclatasvir versus standard care for outpatients with mild COVID-19 infection. METHODS: This was a randomized controlled clinical trial in outpat...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Antimicrob Chemother
Hlavní autoři: Roozbeh, Fatemeh, Saeedi, Majid, Alizadeh-Navaei, Reza, Hedayatizadeh-Omran, Akbar, Merat, Shahin, Wentzel, Hannah, Levi, Jacob, Hill, Andrew, Shamshirian, Amir
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2020
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7798988/
https://ncbi.nlm.nih.gov/pubmed/33338232
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkaa501
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky